Melancholic features related to rimonabant.

Detalhes bibliográficos
Autor(a) principal: Viana, Bernardo de Mattos
Data de Publicação: 2009
Outros Autores: Cano Prais, Hugo Alejandro, Daker, Maurício Viotti
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFOP
Texto Completo: http://www.repositorio.ufop.br/handle/123456789/3767
https://doi.org/10.1016/j.genhosppsych.2008.12.009
Resumo: Introduction: Obesity is currently considered a global epidemic and its prevention and treatment is a major public health concern, demanding treatment which may combine a sociocultural approach, lifestyle modification, nutritional, pharmacological or surgical strategies. Rimonabant, an endocannabinoid antagonist, has been proposed as an agent for an average weight loss of 4 kg. However, the development of anxiety and depressive symptoms can be major side effects. Case Report: A 27-year-old businessman, after using rimonabant (20 mg/day) for 1 month for weight loss, developed a major depressive episode with melancholic features, which remitted after the interruption of rimonabant. Discussion: To our knowledge, a major depressive episode with melancholic or atypical features specifier has not been described since the initiation of rimonabant pharmacological trials. The Hospital Anxiety and Depression Scale, used in the rimonabant trials, assesses several key points of depressive patients. However, it neglects the somatic symptoms that correspond to the additional criterion for both of the mentioned features as well as suicidal ideation. The severity of an episode could also be underestimated depending on the assessment tool or on the clinical interview. Conclusion: There may be an underestimation of depressive melancholic and atypical side effects related to Rimonabant use, due to the lack of consistent assessment with the appropriate screening tools. Pharmacological strategies should be adjunctive for obesity treatment when there is a failure in the lifestyle and nutritional modification strategies. Moreover, deeper global sociocultural changes should be made in the treatment and control of the global obesity epidemic.
id UFOP_c5a6ae819efec6a9d84fb2d2f95df6ff
oai_identifier_str oai:repositorio.ufop.br:123456789/3767
network_acronym_str UFOP
network_name_str Repositório Institucional da UFOP
repository_id_str 3233
spelling Melancholic features related to rimonabant.RimonabantDepressionMelancholic featuresObesityIntroduction: Obesity is currently considered a global epidemic and its prevention and treatment is a major public health concern, demanding treatment which may combine a sociocultural approach, lifestyle modification, nutritional, pharmacological or surgical strategies. Rimonabant, an endocannabinoid antagonist, has been proposed as an agent for an average weight loss of 4 kg. However, the development of anxiety and depressive symptoms can be major side effects. Case Report: A 27-year-old businessman, after using rimonabant (20 mg/day) for 1 month for weight loss, developed a major depressive episode with melancholic features, which remitted after the interruption of rimonabant. Discussion: To our knowledge, a major depressive episode with melancholic or atypical features specifier has not been described since the initiation of rimonabant pharmacological trials. The Hospital Anxiety and Depression Scale, used in the rimonabant trials, assesses several key points of depressive patients. However, it neglects the somatic symptoms that correspond to the additional criterion for both of the mentioned features as well as suicidal ideation. The severity of an episode could also be underestimated depending on the assessment tool or on the clinical interview. Conclusion: There may be an underestimation of depressive melancholic and atypical side effects related to Rimonabant use, due to the lack of consistent assessment with the appropriate screening tools. Pharmacological strategies should be adjunctive for obesity treatment when there is a failure in the lifestyle and nutritional modification strategies. Moreover, deeper global sociocultural changes should be made in the treatment and control of the global obesity epidemic.2014-11-11T17:57:48Z2014-11-11T17:57:48Z2009info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfVIANA, B. M; PRAIS, H. A. C; DAKER, M. V. et al. Melancholic features related to rimonabant. General Hospital Psychiatry, v. 31, p. 583-585, 2009. Disponível em: <http://www.sciencedirect.com/science/article/pii/S0163834309000061>. Acesso em: 03 set. 2014.0163-8343http://www.repositorio.ufop.br/handle/123456789/3767https://doi.org/10.1016/j.genhosppsych.2008.12.009O periódico General Hospital Psychiatry concede permissão para depósito deste artigo no Repositório Institucional da UFOP. Número da licença: 3462660863709.info:eu-repo/semantics/openAccessViana, Bernardo de MattosCano Prais, Hugo AlejandroDaker, Maurício Viottiengreponame:Repositório Institucional da UFOPinstname:Universidade Federal de Ouro Preto (UFOP)instacron:UFOP2019-05-07T13:20:42Zoai:repositorio.ufop.br:123456789/3767Repositório InstitucionalPUBhttp://www.repositorio.ufop.br/oai/requestrepositorio@ufop.edu.bropendoar:32332019-05-07T13:20:42Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP)false
dc.title.none.fl_str_mv Melancholic features related to rimonabant.
title Melancholic features related to rimonabant.
spellingShingle Melancholic features related to rimonabant.
Viana, Bernardo de Mattos
Rimonabant
Depression
Melancholic features
Obesity
title_short Melancholic features related to rimonabant.
title_full Melancholic features related to rimonabant.
title_fullStr Melancholic features related to rimonabant.
title_full_unstemmed Melancholic features related to rimonabant.
title_sort Melancholic features related to rimonabant.
author Viana, Bernardo de Mattos
author_facet Viana, Bernardo de Mattos
Cano Prais, Hugo Alejandro
Daker, Maurício Viotti
author_role author
author2 Cano Prais, Hugo Alejandro
Daker, Maurício Viotti
author2_role author
author
dc.contributor.author.fl_str_mv Viana, Bernardo de Mattos
Cano Prais, Hugo Alejandro
Daker, Maurício Viotti
dc.subject.por.fl_str_mv Rimonabant
Depression
Melancholic features
Obesity
topic Rimonabant
Depression
Melancholic features
Obesity
description Introduction: Obesity is currently considered a global epidemic and its prevention and treatment is a major public health concern, demanding treatment which may combine a sociocultural approach, lifestyle modification, nutritional, pharmacological or surgical strategies. Rimonabant, an endocannabinoid antagonist, has been proposed as an agent for an average weight loss of 4 kg. However, the development of anxiety and depressive symptoms can be major side effects. Case Report: A 27-year-old businessman, after using rimonabant (20 mg/day) for 1 month for weight loss, developed a major depressive episode with melancholic features, which remitted after the interruption of rimonabant. Discussion: To our knowledge, a major depressive episode with melancholic or atypical features specifier has not been described since the initiation of rimonabant pharmacological trials. The Hospital Anxiety and Depression Scale, used in the rimonabant trials, assesses several key points of depressive patients. However, it neglects the somatic symptoms that correspond to the additional criterion for both of the mentioned features as well as suicidal ideation. The severity of an episode could also be underestimated depending on the assessment tool or on the clinical interview. Conclusion: There may be an underestimation of depressive melancholic and atypical side effects related to Rimonabant use, due to the lack of consistent assessment with the appropriate screening tools. Pharmacological strategies should be adjunctive for obesity treatment when there is a failure in the lifestyle and nutritional modification strategies. Moreover, deeper global sociocultural changes should be made in the treatment and control of the global obesity epidemic.
publishDate 2009
dc.date.none.fl_str_mv 2009
2014-11-11T17:57:48Z
2014-11-11T17:57:48Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv VIANA, B. M; PRAIS, H. A. C; DAKER, M. V. et al. Melancholic features related to rimonabant. General Hospital Psychiatry, v. 31, p. 583-585, 2009. Disponível em: <http://www.sciencedirect.com/science/article/pii/S0163834309000061>. Acesso em: 03 set. 2014.
0163-8343
http://www.repositorio.ufop.br/handle/123456789/3767
https://doi.org/10.1016/j.genhosppsych.2008.12.009
identifier_str_mv VIANA, B. M; PRAIS, H. A. C; DAKER, M. V. et al. Melancholic features related to rimonabant. General Hospital Psychiatry, v. 31, p. 583-585, 2009. Disponível em: <http://www.sciencedirect.com/science/article/pii/S0163834309000061>. Acesso em: 03 set. 2014.
0163-8343
url http://www.repositorio.ufop.br/handle/123456789/3767
https://doi.org/10.1016/j.genhosppsych.2008.12.009
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFOP
instname:Universidade Federal de Ouro Preto (UFOP)
instacron:UFOP
instname_str Universidade Federal de Ouro Preto (UFOP)
instacron_str UFOP
institution UFOP
reponame_str Repositório Institucional da UFOP
collection Repositório Institucional da UFOP
repository.name.fl_str_mv Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP)
repository.mail.fl_str_mv repositorio@ufop.edu.br
_version_ 1813002831077048320